| Literature DB >> 29326426 |
Norbert Pardi1, Michael J Hogan1, Frederick W Porter2, Drew Weissman1.
Abstract
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29326426 PMCID: PMC5906799 DOI: 10.1038/nrd.2017.243
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694